News

Debate continues about the methods that the UK’s NICE uses in its appraisals of medical technologies, including whether effects beyond the NHS should be considered using a cost-benefit approach. Examining economic appraisal guidelines issued by other official agencies offers an important opportunity to set NICE’s perspective in context. Ruth Puig-Peiró, an economist at the OHE, is engaged in research that examines how and how much various official UK guidelines differ.

QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for cancer patients, particularly in the last years of life. This post reviews the issues and suggests next steps.

Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care reform. This is the second of two posts that summarises his remarks. It reviews some of the key provision of the law, summarises the factors that will affect its impact, and considers whether US health care will improve as a result.

Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care reform. This is the first of two posts that summarises his remarks. It reviews the background for and the intent of the new legislation signed into law in March 2010.

The law signed in March 2010 eliminated some of the uncertainty about the future of biosimilars in the US. Still unclear is the impact biosimilars actually will have on costs and when any savings might appear.

Pages